Cingulate

Cingulate Net Debt/Equity

The Net Debt to Equity Ratio of Cingulate (CING) as of Nov 6, 2026 is -0.86. In the previous year, Net Debt to Equity Ratio was -0.95 — a change of -9.47% (higher).

Net Debt/Equity

-0.86

YoY

-9.47%

Last updated:

Net Debt to Equity Ratio of Cingulate is 2025 -0.86 . Net Debt to Equity Ratio of Cingulate was 2024 -0.95 . It decreases by -9.47% higher compared to the previous year.

The Cingulate Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2019
2.68 USD
Jan 1, 2020
0.66 USD
Jan 1, 2021
-0.73 USD
Jan 1, 2022
0.13 USD
Jan 1, 2023
-0.50 USD
Jan 1, 2024
-0.95 USD
Jan 1, 2025
-0.86 USD
The Cingulate Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.86-9.47%
-0.95+89.52%
-0.50-483.33%
0.13-117.87%
-0.73-211.99%
0.66-75.54%
2.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Net Debt to Equity Ratio of Cingulate is -0.86 in 2025.

Net Debt to Equity Ratio of Cingulate changed from -0.95 to -0.86, representing a -9.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Cingulate since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Cingulate with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cingulate

All Key Metrics — Cingulate